<DOC>
	<DOCNO>NCT02751905</DOCNO>
	<brief_summary>The primary objective study : To determine mass balance route elimination BIIB074 know metabolite follow administration single oral dose BIIB074 healthy male participant To describe pharmacokinetics ( PK ) BIIB074 know metabolite disposition profile total radioactivity whole blood plasma follow single oral dose . The secondary objective study : To assess safety tolerability BIIB074 healthy participant To identify characterize additional metabolite BIIB074 plasma , urine , feces .</brief_summary>
	<brief_title>Absorption , Metabolism , Excretion Study BIIB074</brief_title>
	<detailed_description />
	<mesh_term>Neuralgia</mesh_term>
	<criteria>Key All subject must practice effective contraception study willing able continue contraception 90 day administration study treatment . Must good health determine Investigator , base medical history screening evaluation . Key History clinically significant cardiac , endocrine , gastrointestinal , hematologic , hepatic , immunologic , metabolic , urologic , pulmonary , neurologic , dermatologic , psychiatric , renal disease , major disease , determine Investigator . Previous exposure BIIB074 . Other unspecified reason , opinion Investigator Biogen , make subject unsuitable enrollment . NOTE : Other protocol define Inclusion/Exclusion criterion may apply .</criteria>
	<gender>Male</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>55 Years</maximum_age>
	<verification_date>June 2016</verification_date>
</DOC>